Related Experiment Video
Updated: May 30, 2026
Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
The cytostatic effects of lovastatin on ACC-MESO-1 cells
Keisuke Asakura1, Yotaro Izumi, Michiko Yamamoto
1Department of Surgery Division of General Thoracic Surgery, School of Medicine, Keio University, Tokyo, Japan.
Background:
Malignant pleural mesothelioma is known to be widely resistant to therapy, and new treatment strategies are needed. Statins are small molecules that suppress the production of multiple hydrophobic substrates in the mevalonate pathway. Although still controversial, statins may decrease the risk of certain cancers such as colon cancer, lung cancer, and prostate cancer. Since the evaluations of the direct effect of statins on malignant mesothelioma are still few, the present study was done to evaluate the effects of lovastatin on ACC-MESO-1 cells in vivo and to investigate the potential mechanisms involved in vitro.
Materials And Methods:
The in vivo effect of lovastatin was evaluated using an NOD/SCID/γnull (NOG) mouse model of human malignant mesothelioma using ACC-MESO-1 cells. Lovastatin was also applied to ACC-MESO-1 cells in vitro and the effects were observed.
Results:
Lovastatin administration reduced primary tumor and metastasis in the NOG mouse model of human malignant mesothelioma. In vitro studies showed that lovastatin administration induced cytostatic effects as per reduced cell viability and cell migration in ACC-MESO-1 cells. These effects were suggested to be dependent on autophagic changes rather than apoptosis. Furthermore, induction of autophagic changes by lovastatin in ACC-MESO-1 cells was independent of mTOR, and was considered to be dependent at least in part on Rac/phospholipase C/ inositol 1,4,5-triphosphate axis.
Conclusions:
These results suggest that it may be possible to utilize statins, or other pharmacological agents that are known to induce mTOR-independent autophagy, as an adjunct to standard treatments in malignant mesothelioma.
Insights
Lovastatin, a type of statin, reduced malignant mesothelioma tumor growth and metastasis in mice. The drug also inhibited cancer cell viability and migration in vitro, suggesting potential as a novel cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Malignant pleural mesothelioma exhibits significant resistance to conventional therapies, necessitating novel treatment strategies.
- Statins, involved in the mevalonate pathway, have shown controversial links to reduced risks of certain cancers.
- Limited research exists on the direct impact of statins on malignant mesothelioma, highlighting the need for further investigation.
Purpose of the Study:
- To evaluate the in vivo effects of lovastatin on malignant mesothelioma.
- To investigate the in vitro mechanisms underlying lovastatin's action on mesothelioma cells.
Main Methods:
- An in vivo study utilized a human malignant mesothelioma (ACC-MESO-1 cells) xenograft model in NOD/SCID/γnull (NOG) mice.
- In vitro experiments involved applying lovastatin to ACC-MESO-1 cells to observe its effects on cell viability and migration.
Main Results:
- Lovastatin administration significantly reduced primary tumor burden and metastasis in the NOG mouse model.
- In vitro, lovastatin induced cytostatic effects, decreasing cell viability and migration in ACC-MESO-1 cells.
- These effects were attributed to autophagy induction, independent of mTOR, and potentially mediated by the Rac/PLC/IP3 pathway.
Conclusions:
- Lovastatin demonstrates therapeutic potential against malignant mesothelioma by reducing tumor growth and metastasis.
- The study suggests that statins or other agents inducing mTOR-independent autophagy could serve as adjuncts to standard mesothelioma treatments.
